STOCK WATCH

SHARES in biotechnology firm Oxford BioMedica rocketed after it announced a new licence and collaboration deal worth up to £71.2m.

Oxford, which listed in 1996, will team up with fellow biotech outfit Bioverativ to develop and make treatments for haemophiliacs.

As part of the deal, Oxford will get £3.6m up front, followed by various milestone payments which will be worth in excess of £71m.

Shares in Oxford shot up by 11.73pc, or 1.26p, to 12p.